Spike with my growth for twenty years
Release time:
2020-08-14
Peak Accompanied My Growth for 20 Years
■ Xu Junxiong
, a pharmaceutical sales company, has been working for 20 years. Recall the bits and pieces of the past, only to find that the original time can carry all the memories, like a video disc, clearly recorded those sour or sweet moments, scene by scene, slowly presented in the brain. Memories of the past, taste the past, evoke some deep in the heart of the aftertaste. In the year of
, I graduated from the health school and went to the society. I was lucky to join Jianfeng Group, the largest and most famous enterprise in Jinhua. After a period of internship in the group clinic, the company arranged me to work in the infirmary of the cable company. "No, I'm the only one in the infirmary." I felt scared, can I do it well? can I do it well? "if you can do it well, just do it with your heart. if you don't understand something, you should ask more questions and consult more." Tang Huamei, head of the group's medical office, encouraged me to say. Although I was not sure, I decided to try hard, because from then on, I had a formal job and didn't have to ask for money from my family to support myself. I was an adult. After arriving at the cable company, I was responsible for the health management of more than 200 people in the whole factory. in addition to working hard, I also used the weekend break to study with the teachers in Jinhua hospital of traditional Chinese medicine. My efforts were recognized by my colleagues and quickly integrated into this big family.
years passed quickly, and I set myself a "great" goal: to take root in Jinhua and buy a two-bedroom apartment of 60 square meters! But the problem is that this goal is difficult to achieve if you rely on the death salary of the infirmary. Just at the beginning of 2001 , Jianfeng Pharmaceutical recruited salesmen for the company, "more work, more pay, no ceiling". I thought for a long time and finally made up my mind to make a dash. Through interviews and training, I successfully became a medical representative of the new special drug company.
To be honest, at that time I could say nothing but youth and passion. Fortunately, newborn calves are not afraid of tigers. As long as they lock in their customers, no matter how high the other party's position is, they will visit them first. Of course, it was always not smooth at first. I was well prepared. Facing the serious face of the other party, I was so nervous that I wanted to leave immediately. At such times, I secretly warn myself to be calm and calm. I am here to recommend good products. I will be turned away in a big deal. If I can't, I will find another department. Someone will always recognize you. This is repeated over and over again, coupled with the guidance of senior brothers and sisters, I slowly grew up, more and more customers recognized me and liked me, and my performance began to show. In those years, I used to be the first in the whole team in terms of sales volume of single hospital products and the first in the whole team in terms of sales volume generated by full coverage of single hospital products. It's hard to run business in the wind and rain, and stay away from my family. Of course, it's hard, but in the constant efforts, I grow up and mature. My house is spacious, my wife is beautiful, my children are lovely, and my happiness index can be imagined.
One day in August, 2011 9 , the leader suddenly talked to me and said that he was going to let me be the assistant to the general manager of Jianfeng Pharmaceutical Sales Company, responsible for the terminal sales in Zhejiang region. The news came so suddenly that I had never learned management and was at a loss. Can I do it? Can I do it? After consulting in many ways and thinking for three days and three nights, I finally made a decision to return to the company to take office.
The new position has new responsibilities, and the change of roles means that the problem must be considered more comprehensively and pay more attention to the overall situation, and the interests of team members must be taken into account while creating performance and profits. Because I have been in the marketing front line for many years, I know the hard work and ideas of the salesmen, as well as their difficulties and hopes for the company. I can think of others in management and strive for a win-win situation between the enterprise and the individual. Over the past few years, the general environment has been beset with difficulties, and the unit price of drug sales has been falling all the way. However, our terminal sales have been able to increase at a 25% rate every year, from no profit in 2012 to turning losses into profits, to an estimated profit of more than 3 million yuan this year.
Over the past 20 years, inspired by the enterprise spirit of "unity and struggle, truth-seeking and innovation, determination to rise to the top, and eternal climbing to the top", I have grown up under the care and care of leaders at all levels of the peak, and have made continuous progress with the support and help of all colleagues. In addition to serving as the executive deputy general manager of the pharmaceutical sales company, I have also obtained a licensed pharmacist certificate and become a member of Zhejiang Pharmaceutical Association, through the self-study examination to obtain a bachelor's degree in business management, self-worth has been continuously realized. Over the past 20 years, I have witnessed the growth of the peak year by year and the continuous record of performance. I am very proud to think that these achievements also have their own modest strength, and I am happy to work in such a company.
I grew up in the peak. The peak is wonderful because of the efforts of our peak people. I naturally blend with the peak and cannot be separated. As a peak person, I will continue to self-study, self-improvement, self-improvement, conscientious, excellence to do their job. I believe that with the unremitting struggle of all our peak people, the peak will move towards a higher development dimension and stand at the peak of the industry.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31